This article is more than 5 years old. Information may no longer be current.
OxiGene drug enters phase 2 trial for myopic macular degeneration
WALTHAM, Mass. — A vascular targeting agent will be investigated in a phase 2 trial for the treatment of myopic macular degeneration, according to a press release from OxiGene, the drug’s developer.
The phase 2 trial is an open-label, dose-ranging, international multicenter study to assess the safety and efficacy of combretastatin A4 prodrug (CA4P) in the treatment of progressive myopic macular degeneration. Patients will be enrolled who have active choroidal neovascularization associated with myopic macular degeneration.
CA4P is part of a novel class of drug candidates called vascular targeting agents, according to OxiGene. CA4P targets the vascular structure of solid tumors and other diseases characterized by the formation of aberrant blood vessels. In ocular diseases that are characterized by abnormal blood vessel growth, CA4P has been shown in preclinical trials to suppress development and induce regression of these blood vessels, according to the press release.
The compound is already in a phase 1/2 trial for treatment of wet age-related macular degeneration, the company noted.